JP6693744B2 - アルツハイマー病の治療方法およびその医薬組成物 - Google Patents

アルツハイマー病の治療方法およびその医薬組成物 Download PDF

Info

Publication number
JP6693744B2
JP6693744B2 JP2015530420A JP2015530420A JP6693744B2 JP 6693744 B2 JP6693744 B2 JP 6693744B2 JP 2015530420 A JP2015530420 A JP 2015530420A JP 2015530420 A JP2015530420 A JP 2015530420A JP 6693744 B2 JP6693744 B2 JP 6693744B2
Authority
JP
Japan
Prior art keywords
compound
dose
disease
pharmaceutical composition
occupancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015530420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528471A5 (enExample
JP2015528471A (ja
Inventor
シュミット，エレン
アーバーグ，ヨハン
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6693744(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2015528471A publication Critical patent/JP2015528471A/ja
Publication of JP2015528471A5 publication Critical patent/JP2015528471A5/ja
Application granted granted Critical
Publication of JP6693744B2 publication Critical patent/JP6693744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015530420A 2012-09-09 2013-09-06 アルツハイマー病の治療方法およびその医薬組成物 Active JP6693744B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US61/698,664 2012-09-09
US201361782084P 2013-03-14 2013-03-14
US61/782,084 2013-03-14
PCT/EP2013/068516 WO2014037532A1 (en) 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018228631A Division JP2019059760A (ja) 2012-09-09 2018-12-06 アルツハイマー病の治療方法およびその医薬組成物

Publications (3)

Publication Number Publication Date
JP2015528471A JP2015528471A (ja) 2015-09-28
JP2015528471A5 JP2015528471A5 (enExample) 2016-10-20
JP6693744B2 true JP6693744B2 (ja) 2020-05-13

Family

ID=49118521

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015530420A Active JP6693744B2 (ja) 2012-09-09 2013-09-06 アルツハイマー病の治療方法およびその医薬組成物
JP2018228631A Pending JP2019059760A (ja) 2012-09-09 2018-12-06 アルツハイマー病の治療方法およびその医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018228631A Pending JP2019059760A (ja) 2012-09-09 2018-12-06 アルツハイマー病の治療方法およびその医薬組成物

Country Status (33)

Country Link
US (4) US9375418B2 (enExample)
EP (1) EP2892563B1 (enExample)
JP (2) JP6693744B2 (enExample)
KR (2) KR20150065680A (enExample)
CN (1) CN104619344A (enExample)
AP (1) AP2015008306A0 (enExample)
AU (1) AU2013311573B2 (enExample)
BR (1) BR112015005117B1 (enExample)
CA (1) CA2883751C (enExample)
CL (1) CL2015000578A1 (enExample)
CY (1) CY1121062T1 (enExample)
DK (1) DK2892563T3 (enExample)
EA (1) EA030448B1 (enExample)
ES (1) ES2703630T3 (enExample)
GE (1) GEP201706776B (enExample)
HR (1) HRP20182069T1 (enExample)
IL (1) IL237369B (enExample)
JO (1) JO3459B1 (enExample)
LT (1) LT2892563T (enExample)
MX (1) MX368305B (enExample)
MY (1) MY182539A (enExample)
NI (1) NI201500031A (enExample)
NZ (1) NZ630589A (enExample)
PL (1) PL2892563T3 (enExample)
PT (1) PT2892563T (enExample)
RS (1) RS58104B1 (enExample)
RU (1) RU2675786C2 (enExample)
SG (1) SG11201501774QA (enExample)
SI (1) SI2892563T1 (enExample)
SM (1) SMT201800678T1 (enExample)
TN (1) TN2015000076A1 (enExample)
TW (1) TWI632909B (enExample)
WO (1) WO2014037532A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JO3639B1 (ar) 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
WO2016179569A1 (en) * 2015-05-07 2016-11-10 Axovant Sciences Ltd. Compositions and methods of treating a neurodegenerative disease
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
KR102473545B1 (ko) * 2016-04-26 2022-12-01 하. 룬드벡 아크티에셀스카브 파킨슨병 환자에서 낙상을 감소시키기 위한 아세틸콜린에스테라아제 억제제 및 아이달로피르딘의 용도
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
KR102015484B1 (ko) 2016-05-18 2019-08-28 수벤 라이프 사이언시스 리미티드 순수한 5-ht6 수용체 길항제와 아세틸콜린에스테라제 저해제의 조합물
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
RS61704B1 (sr) * 2017-05-24 2021-05-31 H Lundbeck As Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele
JP7413368B2 (ja) 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
EP3960174B1 (en) 2020-08-28 2024-10-30 Westfälische Wilhelms-Universität Münster Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use
JP2026514626A (ja) * 2024-03-22 2026-05-13 クイーン アーリック マグネシウム・リドカイン組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
WO1995006638A1 (en) 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
KR20010040254A (ko) 1997-09-29 2001-05-15 스티븐 엘. 네스빗 아미노알킬페놀 유도체 및 관련 화합물
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
AU767009B2 (en) 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
HK1044539A1 (zh) 1999-01-13 2002-10-25 千年药品公司 作为趋化因子受体调节剂的官能化杂环
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
RU2252936C2 (ru) 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009541423A (ja) 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
US20120184532A1 (en) * 2009-07-23 2012-07-19 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
MX2015002879A (es) 2015-07-06
US9375418B2 (en) 2016-06-28
CL2015000578A1 (es) 2015-05-15
TWI632909B (zh) 2018-08-21
TW201414474A (zh) 2014-04-16
RS58104B1 (sr) 2019-02-28
TN2015000076A1 (en) 2016-06-29
EA201590353A1 (ru) 2016-03-31
KR102342127B1 (ko) 2021-12-21
KR20150065680A (ko) 2015-06-15
WO2014037532A1 (en) 2014-03-13
JP2019059760A (ja) 2019-04-18
NZ630589A (en) 2015-12-24
US20140073681A1 (en) 2014-03-13
RU2675786C2 (ru) 2018-12-25
IL237369A0 (en) 2015-04-30
DK2892563T3 (en) 2019-01-21
AU2013311573B2 (en) 2017-10-12
NI201500031A (es) 2016-02-15
US9687473B2 (en) 2017-06-27
PT2892563T (pt) 2019-01-10
US20160256437A1 (en) 2016-09-08
RU2015107877A (ru) 2016-10-27
JP2015528471A (ja) 2015-09-28
CA2883751C (en) 2020-11-24
AU2013311573A1 (en) 2015-03-12
LT2892563T (lt) 2019-01-10
AU2013311573A8 (en) 2015-03-19
IL237369B (en) 2018-11-29
HK1212217A1 (en) 2016-06-10
MX368305B (es) 2019-09-27
CY1121062T1 (el) 2019-12-11
US10660878B2 (en) 2020-05-26
MY182539A (en) 2021-01-25
US9789085B2 (en) 2017-10-17
KR20200137028A (ko) 2020-12-08
ES2703630T3 (es) 2019-03-11
BR112015005117A2 (pt) 2017-07-04
SMT201800678T1 (it) 2019-02-28
CN104619344A (zh) 2015-05-13
AP2015008306A0 (en) 2015-03-31
EP2892563A1 (en) 2015-07-15
SI2892563T1 (sl) 2019-02-28
US20180071254A1 (en) 2018-03-15
SG11201501774QA (en) 2015-05-28
CA2883751A1 (en) 2014-03-13
JO3459B1 (ar) 2020-07-05
BR112015005117B1 (pt) 2022-06-21
GEP201706776B (en) 2017-11-27
PL2892563T3 (pl) 2019-04-30
HRP20182069T1 (hr) 2019-02-08
EP2892563B1 (en) 2018-11-14
EA030448B1 (ru) 2018-08-31
US20160354343A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
EP2892563B1 (en) Pharmaceutical compositions for treating alzheimer's disease
AU2020203107B2 (en) S1P modulator immediate release dosage regimen
EP3209298B1 (en) Compositions for treating insomnia
NL2015272B1 (en) Melatonin formulations and methods for preparation and use.
TW202322816A (zh) 篩選 vmat2 抑制劑之方法
HK1212217B (en) Pharmaceutical compositions for treating alzheimer's disease
OA17281A (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof.
CN107334744A (zh) 盐酸美金刚药物组合物和制法
CN116323604A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂
Martínez-Chávez et al. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib and abemaciclib
Gordi et al. PII‐57: Regadenoson's pharmacokinetics in subjects with varying degrees of renal function
Farré Neuroscience Research Unit, Hospital del Mar Medical Research Institute-IMIM, Parc de Salut Mar, Doctor Aiguader 88, 08003 Barcelona, Spain.
Bertino Jr et al. PII‐58: Effect of a potent CYP3A inhibitor ketoconazole on interindividual variability of CYP3A activity as measured by oral midazolam
Menon et al. PII‐56: The assessment of regional drug absorption of free acid and sodium salt formulations of KS01017 as compared to conventional oral administration in healthy volunteers
UA113770C2 (xx) Спосіб лікування хвороби альцгеймера
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200416

R150 Certificate of patent or registration of utility model

Ref document number: 6693744

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250